BIRC5 and breast cancer: Presence of spontaneous CTL response against MHC-I restricted peptide antigens derived from Survivin in patients suffering from melanoma, breast cancer and leukemia strongly indicates that CD8 T cell restricted epitopes from Survivin are of substantial immunotherapeutic value [98–100].